Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China flag China · Delayed Price · Currency is CNY
11.56
-0.24 (-2.03%)
Jul 30, 2026, 3:05 PM CST

SHE:002900 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-317.84-339.6358.6873.6630.21350.95
Depreciation & Amortization
142.29142.29111.46108.68106.5799.13
Other Amortization
6.136.135.215.353.784.02
Loss (Gain) From Sale of Assets
0.520.52-0.192.6113.311.92
Asset Writedown & Restructuring Costs
31.5931.590-0.822.91-0.69
Loss (Gain) From Sale of Investments
-10.22-10.22-17.78-56.11-59.83-593.2
Provision & Write-off of Bad Debts
-2.62-2.621.22-2.860.591.8
Other Operating Activities
-28.7563.1228.651.51-2.3816.1
Change in Accounts Receivable
174.91174.91-135.48-6.74-10.0349.61
Change in Inventory
31.7431.74-98.88-46.80.6226.49
Change in Accounts Payable
-122.44-122.4476.7-51.4247.19-63.69
Operating Cash Flow
-106.34-36.2530.6935.69144.64-12.53
Operating Cash Flow Growth
---14.02%-75.32%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-202.49-247.73-346.21-299.58-89.22-73.95
Sale of Property, Plant & Equipment
0.680.540.030.220.2711.61
Cash Acquisitions
----15.98--
Divestitures
------4.05
Investment in Securities
-60-114-6.0846.69500-227.73
Other Investing Activities
20.3829.1420.858.128.2115.89
Investing Cash Flow
-241.43-332.04-331.41-260.52419.25-278.23

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-1,058859.55280431471.6
Total Debt Issued
867.741,058859.55280431471.6
Long-Term Debt Repaid
--901.32-643.77-242.47-274.74-282.46
Total Debt Repaid
-724.16-901.32-643.77-242.47-274.74-282.46
Net Debt Issued (Repaid)
143.58156.95215.7737.53156.26189.14
Repurchase of Common Stock
-0.02-0.02-0.22-1.17--
Common Dividends Paid
-93.84-110.28-104.56-41.04-109.34-34.31
Other Financing Activities
4.91208.65202.85-10.41-154.04-198.53
Financing Cash Flow
54.63255.3313.85-15.08-107.12-43.71

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Cash Flow
-293.14-11313.12-239.91456.77-334.48

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-308.83-283.98-315.52-263.8955.42-86.48
Free Cash Flow Growth
------
Free Cash Flow Margin
-37.97%-35.97%-27.86%-22.23%5.39%-9.14%
Free Cash Flow Per Share
-0.95-0.90-1.02-0.860.18-0.28
Levered Free Cash Flow
-250.05-231.31-366.73-243.0383.23-28.2
Unlevered Free Cash Flow
-233.56-214.77-347.16-228.7297.37-19.57

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
33.237.4742.2692.1285.8574.74
Change in Working Capital
72.5672.56-156.54-96.3249.49107.42